Ahren — 2018 Investments
1 investments dated 2018 · listed companies and verified rows first · show all
Cambridge Epigenetixcambridge-epigenetix.cominApr 2018
The company develops a 6-base sequencing platform (duet evoC) that simultaneously profiles methylation (5mC, 5hmC), genetic variants, and fragmentomics from a single cfDNA sample.
BiotechDeep TechHealthtechCambridge
Jason Mellad(Executive Officer, Director)Martin Murphy(Director)Bobby Yerramilli-Rao(Director)Somasundaram Subramaniam(Director)Timothy Rink(Director)Thomas Hulme(Director)
Co-investorsThird Point VenturesAhren Innovation CapitalGV (Google Ventures)New Science VenturesSequoia Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.